Silence Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares
September 08, 2020 07:00 ET
|
Silence Therapeutics
Silence Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares 8 September 2020 LONDON, Silence Therapeutics plc,...
Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets
July 16, 2020 07:00 ET
|
Silence Therapeutics
Silence Announces Mallinckrodt Exercise of Options for Two Additional Complement Targets Silence eligible to receive up to ~$700m milestones per targetDouble-digit royalties on net sales 16 July...
Silence Therapeutics Final results for the year ended 31 December 2019
April 14, 2020 07:00 ET
|
Silence Therapeutics
Final results for the year ended 31 December 2019 April 14, 2020 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of...
Silence Therapeutics to Deliver Virtual Presentation at the Annual Needham Healthcare Conference and Announces Notice of Full Year Results
April 02, 2020 07:00 ET
|
Silence Therapeutics
Silence Therapeutics to Deliver Virtual Presentation at the Annual Needham Healthcare Conference and Announces Notice of Full Year Results 2 April 2020 LONDON, Silence Therapeutics plc (LON: SLN)...
Silence Therapeutics Announces R&D Update
March 25, 2020 07:00 ET
|
Silence Therapeutics
Silence Therapeutics Announces R&D Update 25 March 2020 Re-prioritisation and acceleration of R&D pipeline due to strengthened balance sheet SLN360 brought forward as priority asset, new...
Collaboration with AstraZeneca
March 25, 2020 07:00 ET
|
Silence Therapeutics
Silence Therapeutics Announces Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases 25 March 2020 AstraZeneca to...
Silence Therapeutics Notice of results and R&D day
August 15, 2019 07:00 ET
|
Silence Therapeutics
Silence Therapeutics Notice of Half Year Results and R&D Day August 15, 2019 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and...
SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES
July 18, 2019 06:45 ET
|
Silence Therapeutics
SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES -- Collaboration advances Silence’s proprietary platform...
SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia
January 15, 2019 07:00 ET
|
Silence Therapeutics
SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia January 15, 2019 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery,...
Silence Therapeutics advances next RNAi medicine
December 19, 2018 07:00 ET
|
Silence Therapeutics
Silence Therapeutics advances next RNAi medicine Lipoprotein(a) targeting, an exciting approach to address cardiovascular disease December 19, 2018 LONDON, Silence Therapeutics, PLC (LON: SLN)...